PhRMA
AUGUST 3, 2022
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local media outlets about the potential consequences.
Pharmacy Times
AUGUST 3, 2022
Findings in a new trial show that dietary supplementation of resistant starch has the potential to decrease people’s risk of certain types of gastrointestinal cancers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PhRMA
AUGUST 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines , American medical innovation and our health care system as a whole. But there is another consequence that we can’t leave out: the impact this proposal will have on the biopharmaceutical industry’s contributions to American jobs and the economy.
Pharmacy Times
AUGUST 3, 2022
As leaders, we should ask ourselves if any of our people might feel imposter syndrome and what can we do to calm their anxiety and boost their confidence.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
AUGUST 3, 2022
We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back? It’s been more than two decades since the ground-breaking potential of using electronic health records (EHR) to inform clinical research was first mooted. Since then, progress has been slow, but the industry now has everything it needs to close the feedback loop between science, evidence, and care, said speakers at a recent Co
Pharmacy Times
AUGUST 3, 2022
Increasing population immunity decreased transmission of COVID-19 and allowed for reductions in quarantine and testing, encouraging 2-dose vaccine and booster uptake.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 3, 2022
Pharmacist interventions can provide patient-specific guidance to identify and solve problems with medication regimens to ensure optimal outcomes.
pharmaphorum
AUGUST 3, 2022
Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement with Poseida is by far the larger of the two, with Roche paying $110 million upfront to license rights to off-the-shelf CAR-T therapies aimed at haematological cancers, including one targeting BCMA on phase 1 testing and another targeting CD19 and CD20 that is due to start trials in 2023 – known as the tier 1 candidates.
Pharmacy Times
AUGUST 3, 2022
Participants who initiated treatment with Biktarvy demonstrated superior hepatitis B virus (HBV) DNA suppression and HBV e-antigen seroconversion.
European Pharmaceutical Review
AUGUST 3, 2022
Ph. Eur. The European Pharmacopoeia (Ph. Eur.) Commission has established the mRNAVAC Working Party to begin working on quality standards to support the emerging field of messenger RNA (mRNA) vaccines. The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 3, 2022
Case management programs or pharmacist-delivered high-touch care are critical components in medical specialty drug management.
PharmaVoice
AUGUST 3, 2022
How these latest executive personnel changes are impacting the industry.
Pharmacy Times
AUGUST 3, 2022
Effective pharmacy managers help everyone to see the proverbial forest through the trees.
pharmaphorum
AUGUST 3, 2022
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in the class. The five-year-old Chinese company – which is developing drugs for age-related degenerative diseases – said it will use the proceeds of the Series B to support the clinical development of its RIPK1 inhibitors as well as to expand its pipeline of drug candidates in other classes.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 3, 2022
The next-generation vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and an Omicron variant.
Pharmaceutical Technology
AUGUST 3, 2022
Rigel Pharmaceuticals has signed a licence agreement with Forma Therapeutics for developing, producing and marketing olutasidenib to potentially treat relapsed/refractory acute myeloid leukaemia (R/R AML) and other types of cancer. . Olutasidenib, an investigational agent, is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) that attaches to and hinders mutated IDH1 enzymes.
Pharmacy Times
AUGUST 3, 2022
Ranibizumab-eqrn is the only biosimilar approved for all 5 Lucentis indications.
Pharma Tutor
AUGUST 3, 2022
HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z. About Authors. Avdesh Thassu. MPharm (Nat. Chem.); MBA(Mkt.). admin. Wed, 08/03/2022 - 15:44. Tags. Articles.
Pharmacy Times
AUGUST 3, 2022
Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.
The Happy PharmD
AUGUST 3, 2022
Getting Started as a Medical Writer for Pharmacists in the United States and Canada. In this special webinar session , I had the pleasure of teaming up with one of the coaches at the Happy PharmD, Janan Sawar, to host our guests Milena Murray, June Stevens, and Warda Nawaz discuss how pharmacists can transition into medical writing. . Brief Background on our guests.
Pharmacy Times
AUGUST 3, 2022
IMscin001 analysis shows non-inferior levels of the cancer immunotherapy in the blood compared with intravenous infusion in individuals with advanced non–small cell lung cancer.
pharmaphorum
AUGUST 3, 2022
Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). In the RESILIENT study, Onivyde – a liposomal formulation of the well-established cytotoxic drug irinotecan – was unable to improve overall survival when used as a monotherapy after first-line platinum chemotherapy for SCLC, when compared to generic therapy topotecan.
Pharmacy Times
AUGUST 3, 2022
Ezetimibe (Zetia) is an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total cholesterol.
Pharmaceutical Technology
AUGUST 3, 2022
Gilead Sciences has reported a 1% growth in revenue to $6.3bn in the second quarter (Q2) of 2022 as against $6.2bn in the year-ago quarter. The company attributed the revenue rise to enhanced sales in HIV and oncology products, which was offset partially by reduced sales of Veklury (remdesivir) and hepatitis C virus (HCV) medicines. For the three months ended on 30 June 2022, diluted earnings per share (EPS) declined to $0.91 from $1.21 in Q2 2021.
Pharmacy Times
AUGUST 3, 2022
Dermala helps support hormonal balance, which may help in the treatment of acne.
Pharmaceutical Technology
AUGUST 3, 2022
The proportion of pharmaceutical companies hiring for internet of things related positions rose in July 2022 compared with the equivalent month last year, with 18.2% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 14.6% of companies who were hiring for internet of things related jobs a year ago but a decrease compared to the figure of 19.7% in June 2022.
PharmExec
AUGUST 3, 2022
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
PharmaVoice
AUGUST 3, 2022
The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.
Pharmaceutical Commerce
AUGUST 3, 2022
Association’s director general recommends air cargo developments be closely monitored in second half of year.
Med Ed 101
AUGUST 3, 2022
Estrogen dosing with oral contraceptives can be a challenging issue that may feel overwhelming to many clinicians. The most common synthetic estrogen analog is ethinyl estradiol. In this article, I’ll discuss the reasons why we might select one dose of estrogen over another. Ethinyl estradiol dosing in oral contraceptives can vary significantly.
Pharma Manufacturing
AUGUST 3, 2022
Modern radiopharmaceutical companies are stacked with experienced experts who are laser-focused on correcting the missteps and misfortunes of earlier pioneers
PharmExec
AUGUST 3, 2022
Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.
Pharma Times
AUGUST 3, 2022
The sites will maximise local and global benefits of NHS, research, industry and community partnerships
Pharmaceutical Commerce
AUGUST 3, 2022
New facility will provide lyophilization services.
Expert insights. Personalized for you.
201 
Let's personalize your content